A phase II evaluation of ixabepilone in the treatment of recurrent/persistent carcinosarcoma of the uterus, an NRG Oncology/Gynecologic Oncology Group study
Prospective Phase II trial of ixabepilone in recurrent or persistent uterine carcinosarcoma The objective response rate of nearly 12% did not meet the predefined criteria for clinical activity. Median progression free survival was 1.7 months and median overall survival was 7.7 months.